ImmunoReagents and Sungwoo will partner to distribute top quality antibodies to the South Korean biotech, life science, and medical communities. South Korea is one of the largest biotech markets in Asia-Pacific, next to Japan and China. With strong support from the government, increasing international investment, and a high performing biomedicine sector, the South Korean biotech industry is set to continue its rapid growth. A 2011 report projected that the South Korean biotech industry would witness CAGR growth of 35% between 2010 and 2013. (SBWIRE 2011. Korean Biotech Industry Set for Incessant Growth.)
"This is a promising opportunity for our company." said Ann Black, President and CEO of ImmunoReagents. "Our partnership with Sungwoo will allow us to bring our products to one of the world’s fastest growing biotech markets.”
ImmunoReagents is a leading global manufacturer of quality polyclonal antibodies used in research and in vitro diagnostics. They offer a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species. Antibodies include various levels of cross species absorptions to provide high specificity. The Company also manufactures primary polyclonal antibodies to hormones, cancer markers, cardiac markers and serum proteins. In addition to its vast product lines, ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located on NCSU’s Centennial Campus, the University-owned and operated research park and technology campus.
More information about ImmunoReagents:
Sungwoo Life Sciences provides products to the medical, academic, veterinary, pharmaceutical, and chemical markets, as well as to Bio-Venture, which consists of over 100 companies in Korea.
More information about Sungwoo Life Sciences: http://www.sungwools.com/